August 19th 2025
Specifically, the study found that the muscle that controls eyelid movement, or the orbicularis oculi, “contracts in complex patterns that vary by action and move the eyelid in more than just a simple up-and-down motion."
Eye-opening effects caused by modified transconjunctival lower blepharoplasty
March 12th 2025A recent study assessed the effect of a modified TCLB procedure that added deframing and decompression maneuvers to the LOFC and its support structures to obtain better results for both the lower and upper lids.
Topline results from Ersa Phase 2a trial revealed by Tarsus
December 11th 2023TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
Cosmetic dangers: Part 2-Products banned by the FDA, worsen ocular surface disease
March 14th 2018In Part 2 of her three-part series on cosmetic dangers, Tracy Schroeder-Swartz, OD, MS, FAAO, focuses on the dangers found in cosmetics-particularly cosmetics banned by the FDA and those that may exacerbate ocular surface disease.